References

Pseudomonas aeruginosa: recent advances in vaccine development

10.3390/vaccines10071100 · 2022 · External reference

Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019

10.1016/s0140-6736(22)02185-7 · 2022 · External reference

Vaccines for Pseudomonas aeruginosa: a long and winding road

10.1586/14760584.2014.890053 · 2014 · External reference

Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis

10.1186/s12890-017-0416-4 · 2017 · External reference

Inflammation: a double-edged sword in the response to Pseudomonas aeruginosa infection

10.1159/000455857 · 2017 · External reference

Biofilms: microbial life on surfaces

10.3201/eid0809.020063 · 2002 · External reference

Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective

10.1038/nrmicro2907 · 2012 · External reference

Cystic fibrosis and Pseudomonas aeruginosa: the host-microbe interface

10.1128/cmr.00138-18 · 2019 · External reference

Understanding Pseudomonas aeruginosa-host interactions: the ongoing quest for an efficacious vaccine

10.3390/cells9122617 · 2020 · External reference

The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update

10.1007/s40265-021-01635-6 · 2021 · External reference

Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection

10.1371/journal.pone.0008439 · 2009 · External reference

Lipopolysaccharide modification in Gram-negative bacteria during chronic infection

10.1093/femsre/fuw007 · 2016 · External reference

Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review

10.3389/fmicb.2019.00539 · 2019 · External reference

Antimicrobial resistance in ESKAPE pathogens

10.1128/cmr.00181-19 · 2020 · External reference

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

10.1016/s1473-3099(17)30753-3 · 2018 · External reference

WHO publishes updated list of bacterial priority pathogens

10.1016/j.lanmic.2024.07.003 · 2024 · External reference

Genome-based approach delivers vaccine candidates against Pseudomonas aeruginosa

10.3389/fimmu.2018.03021 · 2018 · External reference

Impact of vaccination on antibiotic usage: a systematic review and meta-analysis

10.1016/j.cmi.2019.06.030 · 2019 · External reference

Vaccines for multidrug resistant Gram negative bacteria: lessons from the past for guiding future success

10.1093/femsre/fuaa054 · 2020 · External reference

The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline

10.1016/s2666-5247(22)00303-2 · 2023 · External reference

Pseudomonas aeruginosa vaccine development: lessons, challenges, and future innovations

10.3390/ijms26052012 · 2025 · External reference

Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy

10.1038/ncomms15480 · 2017 · External reference

Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine

10.1128/iai.70.3.1507-1517.2002 · 2002 · External reference

Double auxotrophy to improve the safety of a live anti-Pseudomonas aeruginosa vaccine

10.3390/vaccines10101622 · 2022 · External reference

Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines

10.3389/fcimb.2026.1840122 · 2026 · External reference

Long term chronic Pseudomonas aeruginosa airway infection in mice

10.3791/51019 · 2014 · External reference

Murine models of acute and chronic lung infection with cystic fibrosis pathogens

10.1016/j.ijmm.2010.08.012 · 2010 · External reference

A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by Pseudomonas aeruginosa

10.1371/journal.ppat.1008311 · 2020 · External reference

A guide to defining and implementing protocols for the welfare assessment of laboratory animals: eleventh report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement

10.1258/la.2010.010031 · 2011 · External reference

Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment

10.1136/vr.116.16.431 · 1985 · External reference

Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets

10.1084/jem.169.1.59 · 1989 · External reference

M-1/M-2 macrophages and the Th1/Th2 paradigm

10.4049/jimmunol.164.12.6166 · 2000 · External reference

Innate immune response in Th1- and Th2-dominant mouse strains

10.1097/01.shk.0000142249.08135.e9 · 2004 · External reference

A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance

10.1128/jb.187.14.4908-4920.2005 · 2005 · External reference

Genome sequence of Pseudomonas aeruginosa strain DK1-NH57388A, a stable mucoid cystic fibrosis isolate

10.1128/genomea.00008-16 · 2016 · External reference

LpxR and PagL expression in live attenuated auxotrophic Pseudomonas aeruginosa vaccines modulates lipid A reactogenicity in vitro while preserving immunogenicity

10.3389/fcimb.2025.1664169 · 2025 · External reference

Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant

10.1128/iai.71.3.1453-1461.2003 · 2003 · External reference

IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa

10.4049/jimmunol.181.7.4965 · 2008 · External reference

Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive

2000 · External reference

Characterization of T cell clones derived from lymph nodes and lungs of Pseudomonas aeruginosa-susceptible and resistant mice following immunization with heat-killed bacteria

10.1046/j.1365-2249.2000.01222.x · 2000 · External reference

Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice

10.1111/j.1699-0463.1997.tb05092.x · 1997 · External reference

Immunological considerations in the development of Pseudomonas aeruginosa vaccines

10.1080/21645515.2019.1650999 · 2020 · External reference

Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis

10.1016/j.jcf.2017.08.012 · 2018 · External reference

Host-pathogen interplay in the respiratory environment of cystic fibrosis

10.1016/j.jcf.2015.02.008 · 2015 · External reference

Secretory immunoglobulin A abrogates inflammatory responses and improves mortality after Pseudomonas pneumonia

10.1097/ta.0b013e3181d486fe · 2010 · External reference

Pseudomonas aeruginosa in chronic lung disease: untangling the dysregulated host immune response

10.3389/fimmu.2024.1405376 · 2024 · External reference

The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type

10.1034/j.1600-0463.2000.d01-64.x · 2000 · External reference

Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response

10.1046/j.1365-2249.2002.01731.x · 2002 · External reference

Innate immune responses to Pseudomonas aeruginosa infection

10.1016/j.micinf.2011.07.011 · 2011 · External reference

Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism

10.1093/infdis/jiv503 · 2016 · External reference

Effector t(h)17 cells give rise to long-lived t(rm) cells that are essential for an immediate response against bacterial infection

10.1016/j.cell.2019.07.032 · 2019 · External reference

Il-17 mediates protective immunity against nasal infection with Bordetella pertussis by mobilizing neutrophils, especially siglec-f(+) neutrophils

10.1038/s41385-021-00407-5 · 2021 · External reference

Innate and adaptive immune responses against Bordetella pertussis and Pseudomonas aeruginosa in a murine model of mucosal vaccination against respiratory infection

10.3390/vaccines8040647 · 2020 · External reference

Development of a broadly protective, self-adjuvanting subunit vaccine to prevent infections by Pseudomonas aeruginosa

10.3389/fimmu.2020.583008 · 2020 · External reference

Multicomponent Pseudomonas aeruginosa vaccines eliciting th17 cells and functional antibody responses confer enhanced protection against experimental acute pneumonia in mice

10.1128/iai.00203-22 · 2022 · External reference

Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia

10.1164/rccm.201202-0182oc · 2012 · External reference

Granulocyte-macrophage colony stimulatory factor enhances the pro-inflammatory response of interferon-gamma-treated macrophages to Pseudomonas aeruginosa infection

10.1371/journal.pone.0117447 · 2015 · External reference

The role of il-10 in immune responses against Pseudomonas aeruginosa during acute lung infection

10.1007/s00441-020-03308-4 · 2021 · External reference

Interleukin-17 is required for control of chronic lung infection caused by Pseudomonas aeruginosa

10.1128/iai.00717-16 · 2016 · External reference

Il-17a impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa

10.1038/srep25937 · 2016 · External reference

Il-17 and il-17-producing cells in protection versus pathology

10.1038/s41577-022-00746-9 · 2023 · External reference

Vaccine efficacies of elastase, exotoxin a, and outer-membrane protein f in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model

10.1099/00222615-38-2-79 · 1993 · External reference

Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein f (oprF) of p. aeruginosa

10.1128/iai.69.5.3510-3515.2001 · 2001 · External reference

Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia

10.1086/315470 · 2000 · External reference

Complete genome sequence of Pseudomonas aeruginosa pao1, an opportunistic pathogen

10.1038/35023079 · 2000 · External reference

Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial

10.1186/gb-2006-7-10-r90 · 2006 · External reference